Anteris Technologies Global Corp. (AVR) Reports 1% HF Hospitalization at 1 Year

Anteris Technologies reported 1-year data for its investigational heart valve, showing 11% heart failure hospitalization and a mean pressure gradient of 8.9 mmHg. The company highlighted single-digit gradients in the small-annulus cohort, a key performance metric.

Original reporting
Published Nov 22, 2026, 10:24 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 22, 2026, 10:33 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Anteris Technologies Global Corp. (AVR) Reports 1% HF Hospitalization at 1 Year — source image
Decision brief

The 30-second read

$AVRBullishMed
01

Why it matters

The disclosed 1% HF hospitalization rate and low gradient are favorable compared with historical benchmarks, potentially de‑risking the product.

02

Market read

First‑time release of promising trial metrics could move AVR stock on the day of the announcement.

03

What to watch

Regulatory pathway and reimbursement uncertainty could temper upside.

Relevance 7/10Novelty 8/10Timing: today

Background

Anteris Technologies Global Corp. (AVR) is a US‑listed biotech developing transcatheter heart‑valve technologies.

Company-level read

Ticker impact

$AVRBullishHigh confidence
Context

Anteris Technologies reported 1% heart‑failure hospitalization at 1 year and a mean pressure gradient of 8.9 mmHg for its investigational valve.

Expected impact

likely upward pressure as market digests favorable clinical outcomes

Evidence & confidence

First‑time disclosure of low hospitalization rate and favorable hemodynamics suggests a competitive advantage for the device.

Market effects

May boost sentiment for cardiac‑device biotech peers.

Limited to US biotech sector.

Low; primarily US‑focused investors.

Counterpoint

Early data may not translate to commercial success; larger trials needed.

Key entities

  • Anteris Technologies Global Corp.

    Developer of investigational transcatheter aortic valve.

Related articles

$AVRMedAI 8/10

Anteris Reports Strong One-Year Results For DurAVR Heart Valve In High-Risk Aortic Stenosis Patients

Anteris Technologies (AVR) reported one-year data for its DurAVR heart valve, showing strong performance in high-risk aortic stenosis patients. Key metrics include 1% hospitalization for heart failure, 8.9 mmHg mean pressure gradient, and 96% of patients with mild or no symptoms post-treatment. The study involved 100 patients with complex conditions. Anteris stock closed at $4.99, up to $5.09 in after-hours trading.

$AVRLow

Anteris Technologies Global Corp. (AVR): Results for announcement to the market Name of entity

Anteris Technologies Global Corp. (AVR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Results for announcement to the market Name of entity: Anteris Technologies Global Corp. (“ATGC”) ARBN: 677 960 235 Reporting period: For the quarter ended September 30, 2026 The attached Form 10-Q Quarterly Report for the quarter ended September 30, 2026 (the “Form

$AVRMedAI 8/10

Small Cap watch: ASX small caps ease after strong week as NewPeak, Orthocell and Anteris advance drilling, sales and data

The S&P/ASX Small Ordinaries Index fell 0.74% on Friday but gained 3.03% over the week. NewPeak Metals completed drilling in Argentina, Orthocell reported record US sales, and Anteris Technologies released positive heart valve data. NewPeak tested gold mineralization, Orthocell sold 92 units of Remplir, and Anteris' valve showed improved haemodynamics in 22 patients.

$AVRMedAI 8/10

Anteris Reports Medium-Size DurAVR THV Outcomes from the EMBARK Study at TCT 2026

Anteris Technologies (NASDAQ: AVR, ASX: AVR) reported 30-day outcomes for its DurAVR THV in 22 patients with medium aortic annuli, showing positive hemodynamic and safety results. The DurAVR THV is being evaluated in the ongoing PARADIGM trial, a global study comparing it to commercially available TAVRs. The company aims to confirm the valve's effectiveness in a randomized setting.